Medical Oncology Analysis
Cancer of the lung remains a major contributor to cancer mortality in the United States. The death rates in men have decreased slightly in the past few years, most likely related to a significant reduction in the percentage of men who smoke. Unfortunately, the death rates in women are still rising due to a more gradual decrease in smoking by women. The case presented in this Integrative Tumor Board is an example of an individual who is severely addicted to cigarettes and who, even in the face of a diagnosed cancer of the lung, cannot give up smoking. Any of the treatment plans presented for this case should focus on the need to help this patient control her addiction using several treatment modalities. I support this approach, and because I have had personal experience in coleading mind/body programs for cancer patients, I have seen the beneficial effects of such programs.
Diagnostic Workup
With regard to the medical oncology aspects of this case, the patient was diagnosed with a non-small-cell carcinoma of the lung (NSCLC), more specifically an adenocarcinoma of the lung, by needle biopsy of a small right-upper-lobe nodule. She underwent a CT scan of the chest and abdomen, a bone scan, and a PET scan to identify possible sites of metastases. The CT scan of the abdomen revealed a 2 cm lesion in the right adrenal, but the PET scan was negative in this area, and it was assumed that the adrenal mass was benign. Bone scan was negative for metastatic disease, and the CT scan and PET scan did not reveal mediastinal disease. However, no mediastinoscopy was carried out. Because the patient did not have definite evidence of distant metastases, she underwent a rightupper lobectomy and was found to have a primary adenocarcinoma of the lung measuring 1.8 × 1.5 × 1.3 cm. Eleven nodes were positive for metastases, but no biopsied mediastinal nodes were positive. She was classified as having stage IIA NSCLC. The patient had a rather comprehensive diagnostic workup preoperatively. Several additional studies would have been helpful in defining the extent of disease preoperatively. Magnetic resonance imaging (MRI) of the right adrenal mass would have been helpful in better defining the nature of this mass. The fact that the PET scan was negative in the area does not rule out malignancy, since there is at least a 10% rate of false-positive and false-negative results. If the MRI results were not definitive in ruling out metastasis, a needle biopsy of the adrenal mass would be indicated. Mediastinoscopy can also be very helpful preoperatively in diagnosing the operability and extent of disease in carcinoma of the lung. 1 This procedure would have added to the accuracy of the staging of the patient's disease.
Therapeutic Approaches
Surgery is the usual form of treatment in patients with stage IIA lung cancer. Adjuvant chemotherapy or radiation therapy does not significantly improve outcome compared to resection alone, as shown by several meta-analyses that indicate only a slight improvement in median survival for patients with completely resected NSCLC who received adjuvant chemotherapy containing cisplatin. One meta-analysis found a 13% reduction in the risk of death, with the absolute benefit at 5 years being only 5%. 2 Therefore, the standard approach in stage IIA NSCLC, in the hands of many oncologists, would be observation rather than chemotherapy. However, the patient presented in this Integrative Tumor Board probably has a worse prognosis than the usually quoted 5-year survival statistic of 50% for a stage IIA lung cancer. This is based on the following. (1) The patient had a relatively small primary cancer of 1.8 cm but rather extensive regional metastases, with 11 nodes being positive. This suggests an aggressive cancer, and the likelihood of at least occult metastases in the mediastinum is quite high. A mediastinoscopy with sampling of more mediastinal nodes would have been helpful. (2) There is a moderate possibility that the patient has metastatic carcinoma in the right adrenal gland, a common site of metastases in NSCLC. In view of this possibility, treatment with chemotherapy may be needed at some point in the patient's course and could be of some benefit in delaying the symptomatic phase of her disease.
Considering the fact that at 5 years after diagnosis, 50% of patients with stage IIA NSCLC have died of their disease, it is important to continue to attempt to improve the outcome for patients. There are a number of clinical trials being carried out by cooperative groups and pharmaceutical companies for patients with stage IIA disease. These include combinations of radiation and radiosensitizing doses of weekly chemotherapy, such as Taxol ® , Taxotere ® , Paraplatin ® , 3 and investigational agents. In addition to these more standard approaches, there are now a number of agents being developed and studied that represent targeted therapies. These therapies consist of antibodies or chemicals that target genes or gene products that are essential for the functioning of the cancer cell. [4] [5] [6] [7] There are therapies that interfere with the blood vessels that feed the tumor (antiangiogenic compounds). 8 There are also therapies that result in apoptosis or programmed death of the cancer cells. 9 These approaches need to be evaluated individually and, if found to have a beneficial effect in animals and humans, should be tested further in an adjuvant setting and in combination with chemotherapy and/or radiation.
It has been shown that radiation therapy as an adjuvant therapy in stage IIA NSCLC does not improve survival and may actually worsen survival. 10 However, it may have a place in treating patients with more aggressive tumors and in combination with other modalities of treatment as discussed above. The patient discussed in the present Integrative Tumor Board should be offered the opportunity to participate in an appropriate clinical trial of radiation or chemotherapy, singly or in combination with newer agents being evaluated for efficacy in NSCLC. In addition, as discussed earlier in this section, she should be given the opportunity to participate in a mind/body program to help her deal with her cancer diagnosis and her addiction to cigarettes and alcohol. The potential beneficial effects of nutritional approaches and naturopathic approaches should be offered to the patient. Whenever these complementary therapies are being investigated in a controlled fashion, patients should also be encouraged to participate in these studies. It is extremely important to involve the patient in the decision making and to return some degree of control back to the patient, which can take various forms, including making oneself feel better by eliciting the relaxation response or by participating in the decision making with one's physician or nurse. The patient's autonomy should be maintained and encouraged wherever possible. The combination of all or some of these approaches will, it is hoped, improve the quality and eventually the length of life of patients with lung cancer.
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The naturopathic approach to the care of our 60year-old white female diagnosed with adenocarcinoma of the lung involves a multidimensional approach to meet her stated priorities of vitality/performance, relationships, longevity, libido, security, and recognition. Note should be made that the patient did not prioritize smoking or drinking as something she wanted to change. With this in mind, we will first look at her history. Our patient in the spring of 2001 complained of a nagging nonproductive cough and a sizable weight loss. She found out about the right-lung mass in September 2001. She did not feel comfortable enough to seek definitive care until late January 2002. In addition, she is a pack-a-day smoker for the past 40 years and continues to smoke at intake, and she has a 4 to 6 glass/day history of wine consumption and is characterized as alcohol dependent.
Because she clearly feels comfortable working in an integrative setting, I would start with her needs around surgery. Working with her oncologist and surgeon, I would recommend that she be supported through her withdrawal period for nicotine and alcohol right before and after surgery. This would mean with the nicotine patch and/or other medications that may be necessary to curb the withdrawal of both nicotine and alcohol (due to being in the hospital) and to cause the least amount of postsurgical stress. If she chooses to stay off alcohol, I would recommend, in addition to social support, L-glutamine-an amino acid that could help reduce alcohol craving, since alcoholics have a biochemical lesion preventing the conversion of glutamic acid (to glutamine, which prevents entry of glutamic acid to the brain) and N-acetylcysteine (to help remove toxic metals and chemicals from the body and to deactivate acetaldehyde, which is a toxic waste product of alcohol metabolism and is present in cigarette smoke). Certainly, metastasis is a concern with surgery, necessitating that fractionated citrus pectin be considered, although studies have been done only on rats and in vitro. 1 One to 2 tablespoons of fractionated citrus pectin in a small amount of hot water taken daily a month before (if available) and a month after may help decrease the risk of tumor cell implantation at distant sites. In addition, preparation for the surgery using homeopathic Arnica (and possibly homeopathic Staphysagria for "knife wounds") right before and after surgery could be of benefit. When she has been granted oral intake status, oral supplements that promote wound healing could be provided as well as support for nicotine withdrawal in the form of Sulfonil (an organic sulfur product that attaches to nicotine receptors) and/or calming herbs such as chamomile, avena (oat straw), passionflower, and others.
The choice to continue to smoke and drink after lifesaving surgery for lung cancer is ultimately the patient's. Most practitioners have witnessed the seeming paradox of a patient with lung cancer smoking outside the doors of a hospital with chemotherapy running into one arm. Although we would all recommend that a patient stop smoking, a concept is emerging that suggests that the process of smoking provides a balance or homeostasis for a deeper need within the body and thus provides a greater benefit to the smoker. I would therefore not recommend that a patient quit smoking unless he or she really desires to do so. A connection could be suggested between exposure as a small child to air contaminants and emotional stress during World War II and her current smoking and alcoholic habits.
Changing the type of cigarette or amount may not be of benefit to our patient. By lowering the smoke yields of carcinogenic polynuclear aromatic hydrocarbons, cigarettes have increased yields of carcinogenic nitrosamines. The latter have been shown to increase adenocarcinoma of the lung, most likely by patterns of deep inhalation to compensate for the lower nicotine levels. The type of cigarette (ie, less toxic chemicals, adhesives, organic tobacco, etc) may or may not be of benefit.
As more and more research points to variation in polymorphisms within individuals, the measurement of our patient's cytochrome P450 in phase 1 detoxification and glutathione (GSH) conjugation in phase 2
